Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

E. Puhó, Marit M. Suttorp, Henrik Frederiksen, Tiny Hoekstra, Olaf M. Dekkers, Lars Pedersen, Suzanne C. Cannegieter, Friedo W. Dekker, Henrik Toft Sørensen

Research output: Contribution to journalArticle

Abstract

Introduction: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with hematological neoplasms remains unclear. We, therefore, aimed to assess the ESA-related risk of VTE, myocardial infarction (MI), and stroke in patients with multiple myeloma (MM) and myelodysplastic syndrome (MDS). Materials and methods: We conducted a population-based cohort study in Denmark, using medical databases to identify 2,114 MDS patients and 3,105 MM patients diagnosed in 2004–2013. Incidence rates per 1,000 person-years and hazard ratios (HRs) with 95% confidence intervals (CIs) for VTE, MI, and stroke associated with ESA treatment were computed. HRs were calculated in time-dependent Cox regression and adjusted for age, sex, MDS prognosis group, comorbidities, and treatments. Results: Incidence rates per 1,000 person-years for VTE, MI, and stroke were 10.8, 8.2, and 16.0 in MDS patients, and 21.9, 10.2 and 9.9 in MM patients without ESA treatment, respectively. MDS patients with ESA treatment had a 1.6-fold increased risk of MI (HR 1.60 [95% CI 0.90–2.86]) and an almost twofold increased risk of stroke (HR 1.94 [95% CI 1.28–2.94]). Adjusted HR for VTE was 1.04 (95% CI 0.57–1.89) compared with MDS patients without ESAs. In MM patients with ESAs compared with patients without ESAs, HRs were 1.41 (95% CI 0.96–2.08) for VTE, 1.23 (95% CI 0.68–2.20) for MI, and 1.63 (95% CI 0.96–2.77) for stroke. Conclusion: ESA use was associated with stroke in MDS patients. Among MM patients, ESA treatment was associated with a higher risk of all cardiovascular events, although all CIs included equivalence.

Original languageEnglish
Pages (from-to)1371-1380
Number of pages10
JournalClinical Epidemiology
Volume10
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Hematinics
Myelodysplastic Syndromes
Multiple Myeloma
Venous Thromboembolism
Confidence Intervals
Stroke
Myocardial Infarction
Therapeutics
Incidence
Hematologic Neoplasms
Denmark
Chronic Renal Insufficiency

Keywords

  • Cohort study
  • Epidemiology
  • Erythropoietin
  • Multiple myeloma
  • Myelodysplastic syndromes
  • Myocardial infarction
  • Pulmonary embolism
  • Stroke
  • Venous thrombosis

ASJC Scopus subject areas

  • Epidemiology

Cite this

Puhó, E., Suttorp, M. M., Frederiksen, H., Hoekstra, T., Dekkers, O. M., Pedersen, L., ... Sørensen, H. T. (2018). Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. Clinical Epidemiology, 10, 1371-1380. https://doi.org/10.2147/CLEP.S172306

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. / Puhó, E.; Suttorp, Marit M.; Frederiksen, Henrik; Hoekstra, Tiny; Dekkers, Olaf M.; Pedersen, Lars; Cannegieter, Suzanne C.; Dekker, Friedo W.; Sørensen, Henrik Toft.

In: Clinical Epidemiology, Vol. 10, 01.01.2018, p. 1371-1380.

Research output: Contribution to journalArticle

Puhó, E, Suttorp, MM, Frederiksen, H, Hoekstra, T, Dekkers, OM, Pedersen, L, Cannegieter, SC, Dekker, FW & Sørensen, HT 2018, 'Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma', Clinical Epidemiology, vol. 10, pp. 1371-1380. https://doi.org/10.2147/CLEP.S172306
Puhó, E. ; Suttorp, Marit M. ; Frederiksen, Henrik ; Hoekstra, Tiny ; Dekkers, Olaf M. ; Pedersen, Lars ; Cannegieter, Suzanne C. ; Dekker, Friedo W. ; Sørensen, Henrik Toft. / Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. In: Clinical Epidemiology. 2018 ; Vol. 10. pp. 1371-1380.
@article{78bb5d20fc97442d9d41b23e49376d76,
title = "Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma",
abstract = "Introduction: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with hematological neoplasms remains unclear. We, therefore, aimed to assess the ESA-related risk of VTE, myocardial infarction (MI), and stroke in patients with multiple myeloma (MM) and myelodysplastic syndrome (MDS). Materials and methods: We conducted a population-based cohort study in Denmark, using medical databases to identify 2,114 MDS patients and 3,105 MM patients diagnosed in 2004–2013. Incidence rates per 1,000 person-years and hazard ratios (HRs) with 95{\%} confidence intervals (CIs) for VTE, MI, and stroke associated with ESA treatment were computed. HRs were calculated in time-dependent Cox regression and adjusted for age, sex, MDS prognosis group, comorbidities, and treatments. Results: Incidence rates per 1,000 person-years for VTE, MI, and stroke were 10.8, 8.2, and 16.0 in MDS patients, and 21.9, 10.2 and 9.9 in MM patients without ESA treatment, respectively. MDS patients with ESA treatment had a 1.6-fold increased risk of MI (HR 1.60 [95{\%} CI 0.90–2.86]) and an almost twofold increased risk of stroke (HR 1.94 [95{\%} CI 1.28–2.94]). Adjusted HR for VTE was 1.04 (95{\%} CI 0.57–1.89) compared with MDS patients without ESAs. In MM patients with ESAs compared with patients without ESAs, HRs were 1.41 (95{\%} CI 0.96–2.08) for VTE, 1.23 (95{\%} CI 0.68–2.20) for MI, and 1.63 (95{\%} CI 0.96–2.77) for stroke. Conclusion: ESA use was associated with stroke in MDS patients. Among MM patients, ESA treatment was associated with a higher risk of all cardiovascular events, although all CIs included equivalence.",
keywords = "Cohort study, Epidemiology, Erythropoietin, Multiple myeloma, Myelodysplastic syndromes, Myocardial infarction, Pulmonary embolism, Stroke, Venous thrombosis",
author = "E. Puh{\'o} and Suttorp, {Marit M.} and Henrik Frederiksen and Tiny Hoekstra and Dekkers, {Olaf M.} and Lars Pedersen and Cannegieter, {Suzanne C.} and Dekker, {Friedo W.} and S{\o}rensen, {Henrik Toft}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/CLEP.S172306",
language = "English",
volume = "10",
pages = "1371--1380",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

AU - Puhó, E.

AU - Suttorp, Marit M.

AU - Frederiksen, Henrik

AU - Hoekstra, Tiny

AU - Dekkers, Olaf M.

AU - Pedersen, Lars

AU - Cannegieter, Suzanne C.

AU - Dekker, Friedo W.

AU - Sørensen, Henrik Toft

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with hematological neoplasms remains unclear. We, therefore, aimed to assess the ESA-related risk of VTE, myocardial infarction (MI), and stroke in patients with multiple myeloma (MM) and myelodysplastic syndrome (MDS). Materials and methods: We conducted a population-based cohort study in Denmark, using medical databases to identify 2,114 MDS patients and 3,105 MM patients diagnosed in 2004–2013. Incidence rates per 1,000 person-years and hazard ratios (HRs) with 95% confidence intervals (CIs) for VTE, MI, and stroke associated with ESA treatment were computed. HRs were calculated in time-dependent Cox regression and adjusted for age, sex, MDS prognosis group, comorbidities, and treatments. Results: Incidence rates per 1,000 person-years for VTE, MI, and stroke were 10.8, 8.2, and 16.0 in MDS patients, and 21.9, 10.2 and 9.9 in MM patients without ESA treatment, respectively. MDS patients with ESA treatment had a 1.6-fold increased risk of MI (HR 1.60 [95% CI 0.90–2.86]) and an almost twofold increased risk of stroke (HR 1.94 [95% CI 1.28–2.94]). Adjusted HR for VTE was 1.04 (95% CI 0.57–1.89) compared with MDS patients without ESAs. In MM patients with ESAs compared with patients without ESAs, HRs were 1.41 (95% CI 0.96–2.08) for VTE, 1.23 (95% CI 0.68–2.20) for MI, and 1.63 (95% CI 0.96–2.77) for stroke. Conclusion: ESA use was associated with stroke in MDS patients. Among MM patients, ESA treatment was associated with a higher risk of all cardiovascular events, although all CIs included equivalence.

AB - Introduction: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with hematological neoplasms remains unclear. We, therefore, aimed to assess the ESA-related risk of VTE, myocardial infarction (MI), and stroke in patients with multiple myeloma (MM) and myelodysplastic syndrome (MDS). Materials and methods: We conducted a population-based cohort study in Denmark, using medical databases to identify 2,114 MDS patients and 3,105 MM patients diagnosed in 2004–2013. Incidence rates per 1,000 person-years and hazard ratios (HRs) with 95% confidence intervals (CIs) for VTE, MI, and stroke associated with ESA treatment were computed. HRs were calculated in time-dependent Cox regression and adjusted for age, sex, MDS prognosis group, comorbidities, and treatments. Results: Incidence rates per 1,000 person-years for VTE, MI, and stroke were 10.8, 8.2, and 16.0 in MDS patients, and 21.9, 10.2 and 9.9 in MM patients without ESA treatment, respectively. MDS patients with ESA treatment had a 1.6-fold increased risk of MI (HR 1.60 [95% CI 0.90–2.86]) and an almost twofold increased risk of stroke (HR 1.94 [95% CI 1.28–2.94]). Adjusted HR for VTE was 1.04 (95% CI 0.57–1.89) compared with MDS patients without ESAs. In MM patients with ESAs compared with patients without ESAs, HRs were 1.41 (95% CI 0.96–2.08) for VTE, 1.23 (95% CI 0.68–2.20) for MI, and 1.63 (95% CI 0.96–2.77) for stroke. Conclusion: ESA use was associated with stroke in MDS patients. Among MM patients, ESA treatment was associated with a higher risk of all cardiovascular events, although all CIs included equivalence.

KW - Cohort study

KW - Epidemiology

KW - Erythropoietin

KW - Multiple myeloma

KW - Myelodysplastic syndromes

KW - Myocardial infarction

KW - Pulmonary embolism

KW - Stroke

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85057750842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057750842&partnerID=8YFLogxK

U2 - 10.2147/CLEP.S172306

DO - 10.2147/CLEP.S172306

M3 - Article

VL - 10

SP - 1371

EP - 1380

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -